Low Molecular Weight Heparin Treatment Decreases MMP-9 Plasma Activity in Patients with Abdominal Aortic Aneurysm

Grzela, Tomasz; Brawura-Biskupski-Samaha, Robert; Jeleńska, M.M.; Szmidt, J

doi:10.1016/j.ejvs.2007.09.008

Cited by 18 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9,[82][83][84][85] Some authors have postulated the complex indirect inhibitory influence of heparin and GAG-sulodexide on MMPs (revealed especially by low-molecular-weight heparin fraction). 12,82 However, there are also data suggesting direct inhibitory properties of dermatan sulfate fraction in sulodexide. 7,84 Recently, the role of interaction between MMPs and endogenous GAGs was postulated as the important mechanism in the development of vascular pathologies, especially chronic venous disease and venous leg ulcers.…”

Section: Heparin and Glycosaminoglycansmentioning

confidence: 99%

Matrix metalloproteinases in the wound microenvironment: therapeutic perspectives

Krejner¹,

Litwiniuk²,

Grzela³

2016

CWCMR

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) are key effector molecules responsible for extracellular matrix (ECM) turnover. They are involved in tissue remodeling and regeneration. Although the main targets for MMPs are ECM components, they are also able to digest a variety of non-ECM molecules including cytokines, their receptors, or carriers. Therefore, the activity of the MMPs remains under tight control. However, when controlling mechanisms are ineffective, MMPs may become highly dangerous molecules, which have a strong destructive effect on affected tissues. Apart from cancer metastasis, aneurysm formation, or airway remodeling in asthma, MMPs have also been identified as main detrimental factors in delayed healing of chronic wounds. In this short review, we describe main representatives of MMPs family, their role in pathophysiology of chronic wounds, as well as current and possible therapeutic strategies for modulation of MMPs' activity, which may be useful in management of chronic wounds.

show abstract

Section: Heparin and Glycosaminoglycansmentioning

confidence: 99%

Matrix metalloproteinases in the wound microenvironment: therapeutic perspectives

Krejner¹,

Litwiniuk²,

Grzela³

2016

CWCMR

View full text Add to dashboard Cite

show abstract

“…Furthermore, recent data have shown that treatment with a low-molecular-weight heparin decreases the levels of MMP-9 in patients with abdominal aortic aneurysm [184]. Again, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (AIIRBs) reduce the raised circulating MMP-9 levels in patients with stable coronary artery disease [185], and the levels of this enzyme are also reduced by ACEI captopril in patients with acute myocardial infarction [186].…”

Section: Inhibition Of Metalloproteinases As Therapeutic Strategies Fmentioning

confidence: 99%

Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases

Gargiulo¹,

Gamba²,

Poli³

et al. 2014

CPD

View full text Add to dashboard Cite

Degradation of the extracellular matrix is an important feature of embryonic development, morphogenesis, angiogenesis, tissue repair and remodeling. It is precisely regulated under physiological conditions, but when dysregulated it becomes a cause of many diseases, including atherosclerosis, osteoarthritis, diabetic vascular complications, and neurodegeneration. Various types of proteinases are implicated in extracellular matrix degradation, but the major enzymes are considered to be metalloproteinases such as matrix metalloproteinases (MMPs) and disintegrin and metalloproteinase domain (ADAMs) that include ADAMs with a thrombospondin domain (ADAMTS).This review discusses involvement of the major metalloproteinases in some age-related chronic diseases, and examines what is currently known about the beneficial effects of their inhibitors, used as new therapeutic strategies for treating or preventing the development and progression of these diseases.

show abstract

“…Finally, heparin inhibits in vitro the expression and activity of some MMPs in smooth muscle cells [76], and recent data show that treatment with a low-molecular heparin decreases the raised plasma levels of MMP-9 in patients with AAA [77]. New selective approaches to MMP-inhibition are in development [29], and only their future application to clinical conditions associated with atherothrombosis, and in particular to PAD, will clarify conclusively the importance of MMPs in atherothrombosis.…”

Section: Mmps and Diabetesmentioning

confidence: 99%

Matrix metalloproteinases and peripheral arterial disease

et al. 2009

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs), a family of enzymes that degrade extracellular matrix, are emerging as important modulators of atherothrombosis. MMPs are produced by inflammatory cells; some of them are also released by activated platelets and play a crucial role in the remodeling processes, leading to atherosclerotic plaque formation, plaque rupture, arterial aneurysm development, and critical limb ischemia. Independent from their matrix degrading activity, MMPs also regulate some cell functions relevant to atherothrombosis, such as platelet activation, neutrophil activation, and vascular reactivity. Plasma levels of some MMPs are increasingly being recognized as a biomarker of atherosclerosis and cardiovascular risk. In peripheral arterial disease, MMPs have been shown to be involved in angiogenesis, arteriogenesis, and the development of arterial calcifications. Increased plasma levels of some MMPs (MMP-2, MMP-9) have been correlated with PAD development and severity. Single nucleotide polymorphisms of the genes encoding for some MMPs have also been associated with the risk of developing peripheral arterial disease and critical limb ischemia. Large prospective observational studies are needed to further demonstrate the role of MMPs in PAD. In perspective, pharmacologic targeting of the expression or activity of MMPs may represent a novel, attractive approach for the treatment of peripheral arterial disease.

show abstract

Low Molecular Weight Heparin Treatment Decreases MMP-9 Plasma Activity in Patients with Abdominal Aortic Aneurysm

Cited by 18 publications

References 5 publications

Matrix metalloproteinases in the wound microenvironment: therapeutic perspectives

Matrix metalloproteinases in the wound microenvironment: therapeutic perspectives

Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases

Matrix metalloproteinases and peripheral arterial disease

Contact Info

Product

Resources

About